

## Special Issue

# Tumor Biomarkers in Gynecology

### Message from the Guest Editors

Gynecological cancers are frequently found in the female population worldwide. Despite the efforts of scientists in implementing screening and early diagnosis programs, only in cervical cancer have we been able to identify an effective method of prevention. In relation to ovarian cancer, the literature has analyzed well-known CA125 and HE4, which are historically reliable, but early-stage diagnosis requires the implementation of more precise biomarkers. Attempts are being made to introduce liquid biopsy for early detection to identify promising biomarkers among microRNAs. Although used for endometrial cancer, the known protein CA-19.9 is imprecise and was surpassed by HE4, whose clinical utility may be limited by the lower sensitivity, but it is strongly related to the prognosis. The new frontier with higher specificity and sensitivity are proteomic biomarkers (i.e., YKL-40, DJ-1) and promising exonal biomarker miRNA (i.e., 21,27 and 223). New horizons are also being studied in this field, looking for new effective markers on peripheral blood for early diagnosis and risk stratification for the development of breast cancer.

### Guest Editors

Dr. Corrado Terranova

Unità Operativa Complessa di Ginecologia—Fondazione Policlinico Universitario Campus Bio-Medico di Roma, Via Alvaro del Portillo 200, 00128 Rome, Italy

Dr. Francesco Plotti

Department of Obstetrics and Gynecology, University Campus Biomedico of Rome, Rome, Italy

### Deadline for manuscript submissions

closed (29 February 2024)



## Biomedicines

an Open Access Journal  
by MDPI

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/si/158682](https://mdpi.com/si/158682)

*Biomedicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).